Has the Chinese Biotech Industry valuation changed over the past few years?

Investors are relatively neutral on the Chinese Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady. The industry is trading close to its 3-year average PS ratio of 6.9x.

Which industries have driven the changes within the Chinese Healthcare industry?

There are no additional sub-industries under this industry.

Chinese (SSE) Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sun, 14 Jun 2026	CN¥752.0b	CN¥109.9b	-CN¥8,632,180,560.00	47.9x	-87.1x	6.8x
Tue, 12 May 2026	CN¥932.6b	CN¥110.1b	-CN¥8,505,640,164.00	54.5x	-109.6x	8.5x
Thu, 09 Apr 2026	CN¥927.3b	CN¥109.9b	CN¥4.7b	45.7x	196.2x	8.4x
Sat, 07 Mar 2026	CN¥901.4b	CN¥109.6b	CN¥5.5b	44.4x	163.5x	8.2x
Mon, 02 Feb 2026	CN¥940.0b	CN¥106.1b	CN¥3.8b	50.6x	249.1x	8.9x
Wed, 31 Dec 2025	CN¥916.9b	CN¥106.1b	CN¥3.8b	47.3x	243x	8.6x
Fri, 28 Nov 2025	CN¥974.1b	CN¥106.1b	CN¥3.8b	51x	258.2x	9.2x
Sun, 26 Oct 2025	CN¥934.0b	CN¥108.2b	CN¥4.9b	51.4x	191.4x	8.6x
Tue, 23 Sep 2025	CN¥970.1b	CN¥107.5b	CN¥5.1b	47.7x	191.9x	9x
Thu, 21 Aug 2025	CN¥994.1b	CN¥108.8b	CN¥7.0b	43.6x	142.9x	9.1x
Sat, 19 Jul 2025	CN¥949.1b	CN¥112.9b	CN¥8.2b	42.4x	115.2x	8.4x
Mon, 16 Jun 2025	CN¥887.1b	CN¥113.0b	CN¥8.3b	37.7x	107x	7.9x
Wed, 14 May 2025	CN¥812.8b	CN¥113.2b	CN¥8.4b	35.6x	96.7x	7.2x
Fri, 11 Apr 2025	CN¥842.9b	CN¥136.1b	CN¥11.7b	30.8x	72.3x	6.2x
Sun, 09 Mar 2025	CN¥853.0b	CN¥136.2b	CN¥11.6b	32x	73.8x	6.3x
Tue, 04 Feb 2025	CN¥797.7b	CN¥136.0b	CN¥10.8b	32.4x	74.1x	5.9x
Thu, 02 Jan 2025	CN¥825.8b	CN¥136.0b	CN¥10.8b	33.1x	76.8x	6.1x
Sat, 30 Nov 2024	CN¥921.3b	CN¥141.7b	CN¥11.2b	36.3x	82.3x	6.5x
Mon, 28 Oct 2024	CN¥937.3b	CN¥143.1b	CN¥12.0b	35.3x	78.2x	6.5x
Wed, 25 Sep 2024	CN¥752.5b	CN¥154.1b	CN¥14.5b	30.5x	52.1x	4.9x
Fri, 23 Aug 2024	CN¥773.2b	CN¥161.4b	CN¥17.4b	28.2x	44.5x	4.8x
Sun, 21 Jul 2024	CN¥849.4b	CN¥161.1b	CN¥17.3b	33.9x	49.1x	5.3x
Tue, 18 Jun 2024	CN¥877.3b	CN¥161.1b	CN¥17.3b	32.5x	50.7x	5.4x
Thu, 16 May 2024	CN¥954.0b	CN¥161.1b	CN¥17.3b	38.9x	55.3x	5.9x
Sat, 13 Apr 2024	CN¥938.7b	CN¥161.4b	CN¥20.3b	37.5x	46.3x	5.8x
Mon, 11 Mar 2024	CN¥978.7b	CN¥165.5b	CN¥22.1b	35.6x	44.3x	5.9x
Wed, 07 Feb 2024	CN¥908.8b	CN¥167.9b	CN¥21.4b	30.7x	42.4x	5.4x
Fri, 05 Jan 2024	CN¥1.1t	CN¥168.1b	CN¥21.5b	39.2x	51x	6.5x
Sun, 03 Dec 2023	CN¥1.1t	CN¥168.1b	CN¥21.5b	41.5x	53.4x	6.8x
Tue, 31 Oct 2023	CN¥1.1t	CN¥175.3b	CN¥25.0b	40.5x	43.4x	6.2x
Thu, 28 Sep 2023	CN¥1.1t	CN¥170.9b	CN¥25.2b	42.7x	42x	6.2x
Sat, 26 Aug 2023	CN¥965.7b	CN¥171.4b	CN¥27.8b	36.3x	34.7x	5.6x
Mon, 24 Jul 2023	CN¥1.1t	CN¥177.4b	CN¥29.9b	38.9x	35.8x	6x
Wed, 21 Jun 2023	CN¥1.1t	CN¥177.4b	CN¥29.3b	38.5x	37x	6.1x


CN Market	-1.46%
Healthcare	-0.43%
Biotech	-1.97%
Biotech	-1.97%

Company	Last Price	7D	1Y	Valuation
688278 Xiamen Amoytop Biotech	CN¥59.33	7.9% +CN¥1.8b	-18.1%	PE23.9x
600201 Jinyu Bio-technology	CN¥12.28	8.8% +CN¥1.1b	61.2%	PE128.7x
688336 Sunshine Guojian Pharmaceutical (Shanghai)	CN¥56.83	3.0% +CN¥1.0b	-1.3%	PE11.8x
688163 Shanghai Serum Bio-Technology	CN¥45.04	23.3% +CN¥922.0m	125.5%	PE100.3x
688062 Mabwell (Shanghai) Bioscience	CN¥28.53	7.3% +CN¥859.9m	-0.2%	PS17.1x

Announcement • Jun 13

Gan & Lee Pharmaceuticals Reports Positive Clinical Results for Insulin Ludefen and Bofanglutide

Gan & Lee Pharmaceuticals announced that two of its core pipeline products in the fields of diabetes and obesity treatment have recently achieved positive clinical results. Insulin Ludefen is an investigational ultra-long-acting once-weekly basal insulin analog independently developed by Gan & Lee Pharmaceuticals. The drug's pivotal Phase III clinical trial in China, SUPER-3, recently met its pre-specified primary endpoint. SUPER-3 is a 26-week, treat-to-target, Phase 3 clinical trial conducted at 80 medical sites across China. The study enrolled 596 adults with type 2 diabetes (T2DM) who had previously been treated with basal-bolus insulin, premixed insulin analogs or dual insulin analog. It evaluated once-weekly Insulin Ludefen compared with once-daily insulin glargine U100 (Lantus®) injection, both in combination with insulin aspart, with or without non-insulin antidiabetic agents. The study met its primary endpoint. In patients with T2DM previously treated with mealtime insulin aspart, premixed insulin analogs, or dual insulin analogs, once-weekly Insulin Ludefen, used as the basal insulin component in combination with prandial insulin aspart, demonstrated superior HbA1c reduction versus once-daily insulin glargine U100. After 26 weeks of treatment, compared with the once-daily glargine insulin U100 regimen, the once-weekly Insulin Ludefen demonstrated superiority in reducing HbA1c levels (change from baseline: -1.58% vs. -1.41%); the estimated between-group treatment difference was -0.17%, and this difference was statistically significant (p=0.0021, GLP-1 RAs. The most common adverse events were gastrointestinal reactions and were mostly mild to moderate and transient, with no new safety signals identified. The above topline results were based on analyses of the modified intention-to-treat (mITT) population and the safety set (SS). Meanwhile, a Phase 2 clinical trial evaluating the efficacy and safety of bofanglutide injection in overweight and obese participants in the United States has also met its primary endpoint. This Phase 2 clinical study was a multicenter, randomized, controlled study that enrolled a total of 326 participants across 20 clinical trial sites in the United States. Bofanglutide injection and placebo were administered under double-blind conditions, while tirzepatide injection served as an open-label comparator. The study evaluated the efficacy and safety of bofanglutide injection in adult participants who had inadequate weight control despite lifestyle interventions and had either a BMI > 30 kg/m², or a BMI = 27 kg/m² accompanied by weight-related comorbidities (excluding type 2 diabetes). Participants were randomized to receive bofanglutide injection 24 mg, 36 mg, or 48 mg Second Quarter or placebo, or 15 mg of tirzepatide injection once weekly for 36 weeks (including a dose-escalation phase). After 36 weeks of treatment, among participants with overweight/obesity without type 2 diabetes, the 48 mg bofanglutide injection group achieved an average weight loss of 15.18%, with no weight loss plateau observed; the 15 mg tirzepatide injection group achieved a mean weight reduction of 16.93%. Bofanglutide injection also demonstrated significant improvements in cardiovascular and metabolic parameters, including blood pressure, waist circumference, and serum uric acid levels. The most common adverse events were gastrointestinal in nature, including nausea, vomiting, and diarrhea; these events were generally mild and transient, and no new safety signals were identified. The above top-line results are based on analyses of the Per-Protocol set (PPS). The Insulin Ludefen SUPER-8 study (a head-to-head comparison with insulin icodec) and other studies in the GRADUAL clinical program of bofanglutide injection are currently underway. Detailed results from these two studies are scheduled to be presented at future scientific conferences and published in international academic journals.

Announcement • Jun 05

Mabwell's 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease

Mabwell announced that its independently developed innovative antibody drug 9MW5211 has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for inflammatory bowel disease (IBD). 9MW5211 is the first candidate drug for its target to enter clinical stage globally.9MW5211 is a highly specific, depleting, and innovative antibody independently developed by Mabwell, designed to precisely intervene in the key pathological mechanisms mediated by abnormal immune cells in autoimmune diseases. The abnormal activation and tissue infiltration of immune cells act as the core driving factors in the occurrence and development of various autoimmune diseases. The target molecule of 9MW5211 is specifically expressed on the surface of pathogenic immune cells and serves as a vital biological marker of their abnormal activation. By selectively recognizing and depleting this population of pathogenic cells, 9MW5211 can effectively block the immune cascade, thereby delaying disease progression and ameliorating clinical symptoms. Through multiple rounds of molecular engineering optimization, 9MW5211 has demonstrated excellent target selectivity. While achieving efficient blockade, it significantly mitigates the risk of non-specific binding, ensuring deep depletion of pathogenic cells highly expressing the target protein. Such a unique mechanism of action is expected to not only bring deeper disease remission but also potentially support an extended dosing interval, thereby enhancing patient compliance and quality of life. Preclinical study results have demonstrated that 9MW5211 exhibits significant therapeutic potential in various mouse models of autoimmune diseases, suggesting its future clinical application may cover multiple major indications. Safety evaluations conducted in cynomolgus monkey models have shown a favorable safety profile. Previously, 9MW5211 has received clearance from FDA to conduct clinical trials for IBD in the US. Its clinical trial applications for multiple indications, including multiple sclerosis (MS), have been accepted by the NMPA. Clinical trial applications for more indications are also being actively advanced.

Chinese (SSE) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Gan & Lee Pharmaceuticals Reports Positive Clinical Results for Insulin Ludefen and Bofanglutide

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Investor sentiment deteriorates as stock falls 16%

Now 20% undervalued

Investor sentiment deteriorates as stock falls 18%

Wedge Industrial Co.,Ltd., Annual General Meeting, Jun 26, 2026

Mabwell's 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease

Investor sentiment improves as stock rises 18%

Now 20% overvalued

First quarter 2026 earnings released: EPS: CN¥0.40 (vs CN¥0.45 in 1Q 2025)

First quarter 2026 earnings released: EPS: CN¥0.048 (vs CN¥0.085 in 1Q 2025)

Full year 2025 earnings released: CN¥0.16 loss per share (vs CN¥0.30 loss in FY 2024)

Full year 2025 earnings released: CN¥0.53 loss per share (vs CN¥0.66 loss in FY 2024)

Jinyu Bio-technology Co., Ltd., Annual General Meeting, May 18, 2026

Price target decreased by 19% to CN¥40.30